infectious diseases news from FierceBiotech
News
Rheumatology: fastest growing subject of trials
New analysis from Nature on the Phase II-IV clinical trials registered with ClinicalTrials.gov shows that oncology studies led all therapeutic areas, followed by central nervous system disorders, Read more...
Breakthrough reported in flu vaccine research
A Japanese chemical company saw its stock shoot up 20 percent this morning, the maximum allowed on the Japanese market, after researchers for NOF and Japan's National Institute of Infectious Diseases Read more...
ALSO NOTED: Rituxan aces RA, leukemia trials; Two die after Gardasil jab; Galapagos earns milestone; and much more...
> Roche's antibody med MabThera (Rituxan) just aced two trials aimed at expanding uses for the drug: one that pitted MabThera against rheumatoid arthritis and another that used it against adult Read more...
Idera shares surge on Merck KGaA pact
Idera is pocketing a $40 million up front fee from Merck KGaA and hopes to make an additional $381 Read more...
Sanaria takes new approach for malaria vaccine
The New York Times profiles Sanaria, a Maryland vaccines company that is taking a cue from Read more...
Pfizer buys Coley for $164M
In what is sure to be one of many acquisitions to come, Pfizer has agreed to purchase Wellesley, MA-based Coley Pharmaceuticals for $8 per share, bringing the total deal to $164 million. Pfizer will Read more...
Lead Therapeutics banks $17M in VC
Lead Therapeutics has pocketed $17 million in its first venture round. Much of that money will go to advance its two candidates for infectious diseases and oncology. Pappas Ventures and ProQuest Read more...
Ranbaxy spins off R&D unit
Ranbaxy, one of India's largest drug makers and a dominant force in the generic drugs business, is spinning off its R&D unit that will develop new medicines. The move will allow the drugmaker to Read more...
Eli Lilly forges $1B diabetes deal
Eli Lilly is putting down a $41 million payment to acquire exclusive rights to MacroGenics' diabetes drug teplizumab in a deal that could be worth more than a billion dollars in total. Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets